The Founder Institute Spring 2023 FI Core Program

Tesu Health has recently been accepted into The Founder Institute‘s Istanbul – Turkey Spring 2023 FI Core Program. This is exciting news for the company as it means they will have access to some of the world’s top entrepreneurs and mentors.

Share this article

The Founder Institute is an American business incubator and startup launch program that was founded in Palo Alto, California in 2009. It has since expanded to over 180 cities in more than 65 countries and has helped over 6,500 entrepreneurs raise over $1.75B in funding.

The Founder Institute‘s mission is to empower talented and motivated people to build impactful technology companies worldwide. The FI Core Program is a structured accelerator program designed to help early-stage startups validate their business ideas, develop their products, and prepare for fundraising. It provides startups with access to a global network of mentors, investors, and peers, as well as a structured curriculum and weekly feedback sessions.

This program will provide Tesu Health with valuable resources and support to help us achieve our goals. This is a significant step for Tesu Health, and our acceptance into the Istanbul – Turkiye Spring 2023 FI Core Program is a testament to the company’s potential impact on the healthcare industry in Turkiye and beyond.

First Patient Enrolled in TH001_1001

Tesu Health is pleased to announce that the first patient has been enrolled in the clinical trial (NCT05668819TH001_1001. The trial evaluates TH-001 versus standard of care in adult patients with prediabetes over a 90-day treatment period with the primary outcome measures being the mean change from baseline in HbA1c (%), FPG (mg/dL), and 2-hour 75 g OGTT (mg/dL) at day 90 between groups.

Share this article

In October 2022 Turkish Medicines and Medical Devices Agency of the Ministry of Health granted Tesu Health approval for a prospective, randomized, controlled clinical trial. The study allows Tesu Health to collect safety and effectiveness data to support a CE Mark certification of TH-001 as a medical device upon completion of the study.


The trial is being led by Principal Investigator Seda Sancak Nurdan, MD, Professor of Endocrinology at the Fatih Sultan Mehmet Training and Research Hospital in Istanbul, Turkiye. An important step in the study was achieved when the first patient was enrolled by the Principal Investigator.


Enrolling the first subject in this important trial is another key milestone for Tesu Health’s clinical program, and we are very pleased to be collaborating with the Fatih Sultan Mehmet Training and Research Hospital research team in evaluating our investigational medical device TH-001 in an indication with a significant unmet medical need.


For more information about the clinical trial TH001_1001 please visit

Bayer Digital Health Startups Map

Tesu Health has recently been included in Bayer’s Digital Health Startups Map. The map is part of Bayer’s Startup Acceleration Program G4A Turkiye and aims to promote innovation in the ecosystem by introducing and supporting startups in the field of health.

Share this article

The updated map features 105 startups founded by entrepreneurs in Turkiye and operating in various categories related to health, such as Healthy Living, Hospital & Pharmacy Solutions, Biotechnology & R&D, Easy Diagnosis & Early Diagnosis, Child Health, and Wearable Technology & IoT. Among these startups, 18 have been selected for Bayer’s G4A Turkiye program, which has been running for 5 years.

Through the program, Bayer provides startups with grants, mentorship, training, and collaboration support, to help them to grow and succeed. The program has already seen great success, with 9 of the startups that received investment reaching a total company valuation of 90.4 million dollars.

Tesu Health‘s inclusion in Bayer’s Digital Health Startups Map is a significant achievement for the company and highlights the importance of our potential to contribute to the growth of the digital health domain. As Bayer provides communication support to all startups by sharing the map on various channels and platforms, it is expected that Tesu Health’s visibility and potential for partnerships and collaborations will increase. The support provided by Bayer through the G4A Turkiye program is a testament to the company’s commitment to promoting innovation and contributing to the growth of the healthcare industry.

Biocube Accelerator Program

Tesu Health is proud to announce its acceptance into the Biocube Accelerator Program, a thematic infrastructure operation and accelerator model project supported by the Istanbul Development Agency. This program is designed to provide entrepreneurs and startups in the biotechnology, pharmaceuticals, and medical devices industries with the resources they need to bring innovative ideas to market and create economic value.

Share this article

As a participant in the Biocube Accelerator Program, Tesu Health will have access to a wide range of resources and support systems, including business, operation, and marketing mechanisms. These resources will enable us to transform our innovative ideas into economic products and create added value in the healthcare industry.

We are excited to be working with Boğaziçi UniversityTeknopark Istanbul, and İSEK-Istanbul Health Industry Cluster, who are all committed to providing the best possible support to entrepreneurs in the biotechnology, pharmaceuticals, and medical devices industries. Their expertise and guidance will be invaluable as we work to develop our products and grow our business.

At Tesu Health, we are dedicated to improving the lives of patients and healthcare providers through the development of innovative technologies. With the support of the Biocube Accelerator Program, we look forward to bringing our ideas to market and making a positive impact in the healthcare industry.

We are grateful for this opportunity and are excited to take part in the Biocube Accelerator Program. We believe that this program will provide us with the resources and support we need to succeed in our mission of improving healthcare for all.

TUBITAK 1512-Entrepreneurship Capital Support Award

Tesu Saglik Teknolojileri A.S. (“Tesu Health“) is proud to announce that we have been honored with the Scientific and Technological Research Council of Turkey (TUBITAK) 1512-Entrepreneurship Capital Support Award for our “Development of evidence-based, prescription digital therapeutics for the treatment of prediabetic individuals” project (project ID: 2210830).

Share this article

The esteemed 1512 Entrepreneurship Support Program, which aims to foster innovation and entrepreneurship by providing capital and other resources, supports entrepreneurs at every stage of their venture, from idea inception to market entry. It is our firm belief that this recognition will provide us with invaluable resources and a platform for continued growth, helping us to transform our technology and innovation-driven business ideas into high-value enterprises that create skilled employment opportunities.

During the first call of 2021, a total of 2395 entrepreneurs submitted business ideas, and Tesu Health was among the applicants. Of these, 1114 entrepreneurs were selected to receive phase 1 support from 63 Implementing Organizations. Subsequently, the business plans of 305 entrepreneurs whose proposals were approved by the Implementing Organizations underwent rigorous evaluation within the scope of stage 2 panels organized by TÜBİTAK. Following the evaluation process, which involved experts from academia, industry, and investment, 132 entrepreneurs were deemed eligible to receive stage 2 support of up to 200,000 TL within the framework of the first call of 2021.

We are honored to be among the recipients of this prestigious award and are committed to utilizing the resources to achieve our mission of transforming healthcare through technology and innovation.

Scroll to Top